论文部分内容阅读
美国国立卫生研究院的Marwick指出,瑞典大规模现场试验未能证明两种百日咳无细胞菌苗有足够的效力,因而使它们未能立即获得美国批准.本文报告作者在试验后1987年8月27日至1988年3月20日继续监察得到的效力资料,说明菌苗的长期保护作用,并讨论监察方法对效力评价的影响.在参加效力试验的1985年3月～1985年9月出生的儿童中,所有实验室证实的百日咳病例均经向瑞典国立细菌学实验室提交的
Marwick of the National Institutes of Health pointed out that a large-scale Swedish field trial failed to prove that two B. pertussis cell-free bacterins were sufficiently potent that they were not immediately approved by the United States. Continue to monitor the efficacy data obtained from March 20 to March 20, indicating the long-term protective effect of the vaccine and discuss the impact of the monitoring method on the evaluation of the effectiveness of children born in the period from March 1985 to September 1985 who participated in the efficacy test , All laboratory confirmed pertussis cases were submitted to the Swedish National Bacteriology Laboratory